Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study

被引：20

作者：

D'Angelo, Salvatore ^{[1
,2
]}

Cantini, Fabrizio ^{[3
]}

Ramonda, Roberta ^{[4
]}

Cantarini, Luca ^{[5
,6
]}

Carletto, Antonio ^{[7
]}

Chimenti, Maria Sole ^{[8
]}

Delle Sedie, Andrea ^{[9
]}

Foti, Rosario ^{[10
]}

Gerli, Roberto ^{[11
]}

Lomater, Claudia ^{[12
]}

Lubrano, Ennio ^{[13
]}

Marchesoni, Antonio ^{[14
]}

Zabotti, Alen ^{[15
]}

Salvarani, Carlo ^{[16
,17
]}

Scrivo, Rossana ^{[18
]}

Scarpa, Raffaele ^{[19
]}

Tramontano, Giuseppina ^{[1
]}

Nannini, Carlotta ^{[3
]}

Lorenzin, Mariagrazia ^{[4
]}

Fabbroni, Marta ^{[5
,6
]}

Martinis, Federica ^{[7
]}

Perricone, Roberto ^{[8
]}

Carli, Linda ^{[9
]}

Visalli, Elisa ^{[10
]}

Rovera, Guido ^{[12
]}

Perrotta, Fabio Massimo ^{[13
]}

Quartuccio, Luca ^{[15
]}

Altobelli, Alessio ^{[18
]}

Costa, Luisa ^{[19
]}

Niccoli, Laura ^{[3
]}

Ortolan, Augusta ^{[4
]}

Caso, Francesco ^{[19
]}

机构：

[1] Rheumatol Inst Lucania IReL, Rheumatol Dept Lucania, Potenza, Italy

[2] Basilicata Ric Biomed, Potenza, Italy

[3] Hosp Prato, Dept Rheumatol, Prato, Italy

[4] Univ Padua, Dept Med DIMED, Rheumatol Unit, Padua, Italy

[5] Univ Siena, Res Ctr Syst Autoinflammatory Dis, Behcets Dis Clin, Siena, Italy

[6] Univ Siena, Dept Med Sci Surg & Neurosci, Rheumatol Ophthalmol Collaborat Uveitis Ctr, Siena, Italy

[7] Univ Verona, Rheumatol Unit, Verona, Italy

[8] Univ Roma Tor Vergata, Dept Med Sistemi, Rheumatol Allergol & Clin Immunol, Rome, Italy

[9] Univ Pisa, Dept Clin & Expt Med, Rheumatol Unit, Pisa, Italy

[10] Vittorio Emanuele Univ Hosp Catania, Rheumatol Unit, Catania, Italy

[11] Univ Perugia, Dept Med, Rheumatol Unit, Perugia, Italy

[12] Osped Mauriziano Umberto 1, Rheumatol Unit, Turin, Italy

[13] Univ Molise, Acad Rheumatol Unit, Dipartimento Med & Sci Salute, Campobasso, Italy

[14] ASST Ctr Specialist Ortoped Traumatol Gaetano Pin, Dept Rheumatol, Milan, Italy

[15] Univ Udine, Acad Hosp S Maria della Misericordia, Dept Med Area, Rheumatol Clin, Udine, Italy

[16] Azienda USL IRCCS, IRCCS, Rheumatol Unit, Dept Internal Med, Reggio Emilia, Italy

[17] Univ Modena & Reggio Emilia, Modena, Italy

[18] Sapienza Univ Roma, Reumatol, Dipartimento Med Interna & Specialita Med, Rome, Italy

[19] Univ Naples Federico II, Sch Med & Surg, Dept Clin Med & Surg, Rheumatol Unit, Naples, Italy

来源：

FRONTIERS IN PHARMACOLOGY | 2019年 / 10卷

关键词：

psoriatic arthritis; biological drugs; adalimumab; retention rate; real-life; LONG-TERM TREATMENT; ANKYLOSING-SPONDYLITIS; RHEUMATOID-ARTHRITIS; TREATMENT RESPONSE; DRUG SURVIVAL; PREDICTORS; THERAPIES; RECOMMENDATIONS; PERSISTENCE; MANAGEMENT;

D O I：

10.3389/fphar.2019.01497

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: Few studies have evaluated the effectiveness of adalimumab in the real-life setting in psoriatic arthritis (PsA). Objective: To evaluate the 2-year retention rate of adalimumab in PsA patients. Potential baseline parameters influencing persistence on treatment were also evaluated. Methods: PsA patients from 16 Italian Rheumatology Units treated with adalimumab as first- or second-line biological therapy were retrospectively evaluated. Adalimumab retention rate was evaluated at 12 and 24 months. Logistic regression was used to evaluate the association between predictor variables and adalimumab retention rate. Results: From 424 patients (53.5% male, aged 48.3 +/- 12.8 years) who started treatment with adalimumab, 367 (86.6%) maintained treatment for 12 months and 313 (73.8%) for 2 years. At 24-months, Disease Activity in PsA (DAPSA) remission (defined as <= 4) and Low Disease Activity (LDA) (<= 14) were achieved in 22.8% and 44.4% of patients, respectively. Adalimumab treatment significantly decreased the number of tender (7.0 +/- 5.7 at baseline vs. 2.3 +/- 3.5 at 24 months, p < 0.001) and swollen joints (2.7 +/- 2.8 at baseline vs. 0.4 +/- 0.9 at 24 months, p < 0.001), DAPSA (25.5 +/- 10.9 at baseline vs. 11.0 +/- 8.4 at 24 months, p < 0.001), PASI (5.3 +/- 5.7 at baseline vs. 2.7 +/- 2.8 at 24 months, p < 0.001) and CRP (3.8 +/- 6.3 at baseline vs. 1.2 +/- 1.7 at 24 months, p < 0.001). Among a range of laboratory and clinical variables, only female gender was associated with improved adalimumab persistence at 24 months (OR: 1.98, 95% CI: 1.2-3.2, p = 0.005). Conclusions: Independent of a range of predictor variables, adalimumab was shown to be effective, while maintaining a high retention rate after 2 years in PsA patients.

引用

页数：7

共 28 条

[1] Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study [J].

Aaltonen, Kalle ;

Heinonen, Arto ;

Joensuu, Jaana ;

Parmanne, Pinja ;

Karjalainen, Anna ;

Varjolahti-Lehtinen, Tuire ;

Uutela, Toini ;

Puurtinen-Vilkki, Maija ;

Arstila, Leena ;

Blom, Marja ;

Sokka, Tuulikki ;

Nordstrom, Dan .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017, 46 (06) :732-739

[2] ANTI-TNF AGENTS AS THERAPEUTIC CHOICE IN IMMUNE-MEDIATED INFLAMMATORY DISEASES: FOCUS ON ADALIMUMAB [J].

Armuzzi, A. ;

Lionetti, P. ;

Blandizzi, C. ;

Caporali, R. ;

Chimenti, S. ;

Cimino, L. ;

Gionchetti, P. ;

Girolomoni, G. ;

Lapadula, G. ;

Marchesoni, A. ;

Marcellusi, A. ;

Mennini, F. S. ;

Salvarani, C. ;

Cimaz, R. .

INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2014, 27 :11-32

[3] Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease [J].

Burmester, Gerd R. ;

Panaccione, Remo ;

Gordon, Kenneth B. ;

McIlraith, Melissa J. ;

Lacerda, Ana P. M. .

ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (04) :517-524

[4] Psoriatic arthritis: treatment strategies using biologic agents [J].

D'Angelo, S. ;

Palazzi, C. ;

Olivieri, I. .

REUMATISMO, 2012, 64 (02) :113-121

[5]

D'Angelo S, 2017, OPEN ACCESS RHEUMATO, V9, DOI 10.2147/OARRR.S56073

[6] Improvements in diagnostic tools for early detection of psoriatic arthritis [J].

D'Angelo, Salvatore ;

Palazzi, Carlo ;

Gilio, Michele ;

Leccese, Pietro ;

Padula, Angela ;

Olivieri, Ignazio .

EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (11) :1209-1215

[7] Adalimumab for long-term treatment of psoriatic arthritis - Forty-eight week data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial [J].

Gladman, Dafna D. ;

Mease, Philip J. ;

Ritchlin, Christopher T. ;

Choy, Ernest H. S. ;

Sharp, John T. ;

Ory, Peter A. ;

Perdok, Renee J. ;

Sasso, Eric H. .

ARTHRITIS AND RHEUMATISM, 2007, 56 (02) :476-488

[8] Treatment Response, Drug Survival, and Predictors Thereof in 764 Patients With Psoriatic Arthritis Treated With Anti-Tumor Necrosis Factor α Therapy Results From the Nationwide Danish DANBIO Registry [J].

Glintborg, Bente ;

Ostergaard, Mikkel ;

Dreyer, Lene ;

Krogh, Niels Steen ;

Tarp, Ulrik ;

Hansen, Michael Sejer ;

Rifbjerg-Madsen, Signe ;

Lorenzen, Tove ;

Hetland, Merete Lund .

ARTHRITIS AND RHEUMATISM, 2011, 63 (02) :382-390

[9] Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry [J].

Glintborg, Bente ;

Ostergaard, Mikkel ;

Krogh, Niels Steen ;

Dreyer, Lene ;

Kristensen, Hanne Lene ;

Hetland, Merete Lund .

ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (11) :2002-2008

[10] European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update [J].

Gossec, L. ;

Smolen, J. S. ;

Ramiro, S. ;

de Wit, M. ;

Cutolo, M. ;

Dougados, M. ;

Emery, P. ;

Landewe, R. ;

Oliver, S. ;

Aletaha, D. ;

Betteridge, N. ;

Braun, J. ;

Burmester, G. ;

Canete, J. D. ;

Damjanov, N. ;

FitzGerald, O. ;

Haglund, E. ;

Helliwell, P. ;

Kvien, T. K. ;

Lories, R. ;

Luger, T. ;

Maccarone, M. ;

Marzo-Ortega, H. ;

McGonagle, D. ;

McInnes, I. B. ;

Olivieri, I. ;

Pavelka, K. ;

Schett, G. ;

Sieper, J. ;

van den Bosch, F. ;

Veale, D. J. ;

Wollenhaupt, J. ;

Zink, A. ;

van der Heijde, D. .

ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (03) :499-510

← 1 2 3 →